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pen accessAbstract Objectives: Levosimendan improves the function of stunned myocardium and cardiac
performance in heart failure without signiﬁcantly increasing myocardial oxygen consumption.
We evaluated the effects of levosimendan on hemodynamics and coronary grafts blood ﬂow
(CBF) in patients with left ventricular dysfunction undergoing pump coronary artery bypass grafts
(CABG) surgery using transit time ﬂow meter (TTFM).
Methods: Twenty patients with stable angina and left ventricular ejection fraction 30–50% sched-
uled for elective CABG surgery were randomized to receive levosimendan (0.1 mg/kg/min) or pla-
cebo, started immediately after induction of anesthesia and continued for 24 h in ICU. Coronary
bypass grafts ﬂow was measured 30 min after termination of cardiopulmonary bypass (CPB). Flow
curve pattern, mean graft ﬂow, and pulsatile index (PI) were measured and analyzed. Hemodynam-
ics was collected serially at ﬁve time points.
Results: Mean ﬂow in all grafts was signiﬁcantly higher in the Levosimendan group in comparison
to control group (p< 0.05). When we compared mean ﬂow between different types of grafts in Lev-
osimendan group, we found that venous sequential grafts had higher ﬂow than non-sequential graft
(p< 0.001) and arterial grafts (p= 0.005). Also saphenous vein grafts (SVG) had higher ﬂow in
comparison to left internal mammary artery (LIMA) grafts (p= 0.004). As regard PI, it was alsoarm, Giza, Egypt. Tel.: +20
.com (O.M. Asaad).
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46 O.M. Asaad, M.S. Hanafymore signiﬁcant in the Levosimendan group for all grafts (p< 0.001) in comparison to control
group. Intragroup comparison of PI values between different types of grafts in Levosimendan
group showed more signiﬁcant PI values in sequential grafts (p= 0.002) in relation to SVG, and
also it was more signiﬁcant in comparison to LIMA grafts (p= 0.0027).
Conclusions: Levosimendan signiﬁcantly increased the ﬂow in arterial and vein grafts after CPB,
and improved hemodynamics compared with placebo.
ª 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Levosimendan is a new calcium-sensitizing agent that has been
developed for the treatment of decompensated heart failure.
Levosimendan enhances myoﬁlaments contractility mainly
via its calcium-sensitizing actions by binding to cardiac tropo-
nin C in a calcium-dependent manner and induces peripheral
and coronary vasodilation by opening the adenosine triphos-
phate-sensitive potassium channels [1,2].
Administration of levosimendan in patients undergoing
elective cardiac surgery signiﬁcantly increased cardiac output,
heart rate and stroke volume without signiﬁcantly increasing
myocardial oxygen consumption or changing the utilization
of myocardial substrates. A similar ‘neutral’ effect of levosim-
endan on myocardial energetics has also been demonstrated in
healthy volunteers, whereas adrenergic agonists such as dobu-
tamine increased oxygen consumption in addition to contrac-
tility [3]. Moreover, a recent study demonstrated that
levosimendan is safe in patients with acute coronary syndrome
who underwent a percutaneous coronary intervention (PCI),
and improves the function of stunned myocardium [4].
Several methods have been used to assess graft patency
intraoperatively, including manual palpation of the graft, di-
rect probing of the anastomosis, graft patency testing with syr-
inge, and ultrasound-based ﬂow meters such as Doppler and
transit time ﬂow measurement (TTFM) and intraoperative
angiography. Among those methods, TTFM has been used
with increasing frequency because it is considered to be a con-
venient and reliable way to document graft patency and subse-
quent correction of graft related problems intraoperatively
[5,6].
The aim of this study was to detect the effects of Levosim-
endan on coronary graft ﬂow after cardiopulmonary bypass,
by using transit time ﬂow meter in patients undergoing elective
CABG surgery.2. Patients and methods
2.1. Patient population and study design
This prospective, randomized trial was conducted at The Chest
Diseases Hospital, Kuwait over a period of 6 months starting
from January 2009 to June 2009. The ethics and review board
at the hospital approved the study protocol, and all patients
gave written informed consent. Twenty patients were included
after they satisﬁed the following criterion: isolated non-urgent
on-pump CABG surgery with left ventricular ejection fraction
30–50%. Exclusion criteria were; valvular heart disease,
marked mechanical obstructions affecting ventricular ﬁlling
or outﬂow or both, evolving myocardial infarction (<7 days),
preoperative hemodynamic instability (severe hypotension orserious arrhythmias), severe renal impairment (plasma
creatinine > 2.5 mg/dL) and severe hepatic disease (liver
enzymes > 2 times the upper limit of normal).
The patients were randomized by sealed envelopes to the
Levosimendan group (10 patients) or the placebo group (10
patients). Nurses who did not participate in the study prepared
the drugs in 50 ml syringes according to the table of random-
ization. Drugs administration and data collection were per-
formed in a double-blind fashion in which neither the
patients nor the medical team were aware about the injected
drugs. The treatment group received levosimendan (Simdax;
Orion Corp, Espoo, Finland), (5 ml of the drug 2.5 mg/ml di-
luted in 500 ml 5% dextrose solution ﬁ 0.025 mg/ml solution
for infusion) at a dose of 0.1 mg/kg/min started immediately
after the induction of anesthesia and continued for 24 h in
ICU. According to the standard practice in the hospital, no
bolus dose of the drug was administered because of concern
for severe hypotension associated with the bolus dose of the
drug. The control patients received a placebo (thiamin-colored
5% glucose) infusion of equivalent volume over the same time
interval.
2.2. Methods
2.2.1. Anesthesia and surgical techniques
Two hours before surgery, an equipotent dose of oral meto-
prolol was given for the patients who were on preoperative
b-blockers. Thirty minutes before the induction of anesthesia,
the patients were premedicated with intramuscular morphine
0.1 mg/kg. After reaching the operating theater, the standard
monitors were attached to the patients. A continuous cardiac
output pulmonary artery catheter (Edwards Lifesciences, Ir-
vine, CA), inserted after the induction of anesthesia, also a uri-
nary bladder catheter with a temperature probe was inserted
for temperature and urine-output monitoring. All patients
were induced with midazolam (0.05 mg/kg), sufentanil
(0.5 lg/kg), propofol (1.0 mg/kg), and an intubating dose of
rocuronium. Anesthesia was maintained with air/O2, sevoﬂu-
rane, and sufentanil (infusion 0.5 lg/kg/h). Mechanical venti-
lation was maintained with a tidal volume of 6–8 ml/kg and
frequency of 10–12 breaths/min. During CPB, anesthesia was
maintained using propofol infusion at a rate of 3 mg/kg/h.
Heparin sulfate 4 mg/kg was administered prior to CPB
and supplemented as needed to maintain an activated clotting
time (ACT) of at least 400 s. CPB was conducted with a roller
pump (Stockert S3, Sorin Group, Deutschland, Mu¨nchen,
Germany) using membrane oxygenator (Medtronic, USA)
and 40-l arterial line ﬁlter with non-pulsatile perfusion (at a
ﬂow rate of 2.4 l/min/m2). Saint Thomas cardioplegia solution
(potassium 20 mmol/l) was delivered through the antegrade
and retrograde routes (diluted with blood 1:4) every 20 min.
Systemic temperature was allowed to drift to 35 C.
Figure 1 The trace shows a normal curve with its parameters.
Qmean, Mean ﬂow; Qmax, maximum ﬂow; Qmin, minimum ﬂow; PI,
pulsatility index; BF, backward ﬂow [7].
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(PCWP) was kept between 13 and 16 mm Hg using IV ﬂuids.
Dobutamine was administered in both groups if the cardiac in-
dex (CI) fell below 2.0 l/min/m2 with PCWP above 15 mm Hg
and a mean arterial blood pressure (MAP) below 65 mm Hg.
Dobutamine was initiated and increased until haemodynamic
targets were achieved (CI 2.3–2.5 l/min/m2). When a patient
had an MAP 660 mm Hg and systemic vascular resistance
(SVR) 6 600 dynes/s/cm5, a Norepinephrine infusion was also
started. The treatment goal was to achieve a MAP
P70 mm Hg, CI P2.4 l/min/m2, PCWP <18 mm Hg, and
SVR <1200 dynes/s/cm5.
After separation from CPB and removal of the aortic can-
nula, heparin activity was neutralized with protamine sulfate.
Upon arrival in the ICU, the patient’s condition was evaluated
and kept sedated for 2 h with propofol 0.5 mg/kg/h plus inter-
mittent boluses of morphine (2–4 mg every 30 min as needed)
until hemodynamic variables and temperature were stable.
Weaning from mechanical ventilation and tracheal extubation
followed a standard protocol.
2.2.2. Intraoperative measurement of grafts ﬂow by TTFM
Graft ﬂow measurements were performed 30 min after the ter-
mination of CPB and after the reversal of heparin. MAP was
maintained between 80 and 90 mm Hg during the ﬂow mea-
surement. The same transit time ﬂowmeter (MediStim VQ-
1101, MediStim ASA, Oslo, Norway) was calibrated and used
in all patients. The TTFM probe was perfectly ﬁtted around
the graft by using different probe sizes to avoid distortion or
compression of the graft. The following variables can be ob-
tained and analyzed: (1) ﬂow curve pattern; (2) mean graft
ﬂow; (3) pulsatility index (PI) ([maximal ﬂow  minimal
ﬂow]/mean ﬂow); (4) percentage of backward ﬂow (% BF)
(or it is called insufﬁciency ratio – IR), as the amount of ﬂow
through the graft directed backward across the anastomotic
site and (5) diastolic ﬁlling percentage (DF%) (Fig. 1) [7].
To correctly address TTFM ﬁndings, ﬂow curves, pulsatile
index (PI) and mean ﬂow values should be evaluated simulta-
neously. The curves are coupled with the ECG tracing to cor-
rectly differentiate systolic from the diastolic ﬂow. In a patent
coronary graft, blood ﬂows mainly during diastole with mini-
mal systolic peaks taking place during the isovolumetric ven-
tricular contraction (QRS complex) [8]. Mean ﬂow is largely
dependent on the quality of the native coronary artery, and
low mean ﬂow can be expected in fully patent anastomoses
whenever the target territory has a poor runoff [9]. Mean ﬂows
of less than 15 ml/min is considered to be questionable. The PI
is a good indicator of the ﬂow pattern and, consequently, of
the quality of the anastomosis. The pulsatility index (PI) value
should ideally be between 1 and 5. The possibility of a techni-
cal error in the anastomosis increases for higher PI values > 5
[10], DF < 50% and/or insufﬁciency ratio (% BF values)
greater than 3% [8].
2.2.3. Data collection
Heart rate (HR), mean arterial pressure (MAP), central venous
pressure (CVP), cardiac index (CI), systemic vascular resis-
tance index (SVRI), pulmonary capillary wedge pressure
(PCWP), and pulmonary vascular resistance index (PVRI)
and mixed venous oxygen saturation (SvO2) were collected
after the induction of anesthesia and before the start of study
drugs (base line) (T0), 15 min post CPB (T1), at the end of theoperation (T2), 6 h after ICU admission (T3) and 24 h after
ICU admission(T4). Troponin I and arterial lactate were col-
lected at base line after the induction of anesthesia, on ICU
admission, 6 and 24 h from ICU admission. Duration of
tracheal intubation, ICU stay and mortality among the study
patients were documented.
2.2.4. Statistical analysis
Data were statistically described in terms of range,
mean ± standard deviation (±SD), 95% CI of the mean,
median, frequencies (number of cases) and percentages when
appropriate. Comparison of quantitative variables between
the study groups was done using Mann Whitney U test for
independent samples when comparing two groups and Kruskal
Wallis test with Conover Inman posthoc test in comparing
more than two groups. Within group comparison of quantita-
tive variables was done using Wilcoxon signed rank test for
paired (matched) samples. For comparing categorical data,
Chi square (v2) test was performed. Exact test was used instead
when the expected frequency is less than ﬁve. A probability va-
lue (p value) less than 0.05 was considered statistically signiﬁ-
cant. All statistical calculations were done using computer
programs Microsoft Excel 2003 (Microsoft Corporation,
NY, USA) and SPSS (Statistical Package for the Social
Science; SPSS Inc., Chicago, IL, USA) version 15 for Micro-
soft Windows.
Sample size calculation was done using mean ﬂow as it was
considered the primary outcome of our study with one con-
trol(s) per experimental subject. In a previous study, the re-
sponse within each subject group was normally distributed
with a standard deviation 10. If the true difference in the exper-
imental and control means is 20, we will need to study around
10 experimental subjects and 10 control subjects to be able to
reject the null hypothesis that the population means of the
experimental and control groups are equal with 80% power.
Type I error probability associated with this test of this null
hypothesis is 0.05. Calculations were done using PS Power
and Sample Size Calculations software, version 2.1.30 for
MS Windows (William D. Dupont and Walton D. Vanderbilt,
USA).
Table 2 Operative data.
Variable Levosimendan
(n= 10)
Placebo
(n= 10)
p-value*
Aortic cross-clamp (min) 59 ± 11.8 67 ± 12.5 0.158
Cardiopulmonary bypass (min) 103 ± 25 112 ± 22 0.404
Grafts/patient 2.8 ± 0.5 2.7 ± 0.7 0.717
Number of grafts-total (n) 26 24
LIMA 10 9 0.825
Saphenous vein grafts 16 15 0.794
Sequential grafts 2 3 0.925
Total distal anastomosis (n) 28 27
LAD 10 10 0.858
Diagonal 5 4 0.952
Cx system 7 8 0.934
RCA system 6 5 0.946
Data are presented as mean ± SD.
LAD, left anterior descending artery; Cx system, circumﬂex system;
RCA system, right coronary artery system; LIMA, left internal
mammary artery.
* p-value, levo. vs. placebo.
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Twenty patients were enrolled and completed the study. There
were no statistically signiﬁcant differences in demographic
data, preoperative ejection fraction and risk factors among
the two studied groups (Table 1). Operative data were similar
among the two groups. Types of grafts (LIMA, SVG or Radial
artery) and distribution of anastomosis (Lt System, right sys-
tem or sequential) were also similar between the two studied
groups. LIMA grafts were only anastomosed to LAD (Table
2).
The changes in hemodynamic parameters are shown in
Table 3. At baseline, there were no differences between Levo-
simendan and control group in hemodynamic variables. In
contrast, post CPB and during ICU course (T1–T4), the re-
corded HR showed a signiﬁcant increase in the two groups
in comparison to base line but it was signiﬁcantly higher in
Levosimendan group (p< 0.001). MAP showed a signiﬁcant
increase in both groups in relation to baseline to reach the
maximal levels at 24 h after ICU admission and there was a
signiﬁcant difference between the two groups (p< 0.005). Fif-
teen minutes post CPB (T1) and at the end of surgery (T2),
SVRI and PVRI, dropped signiﬁcantly in both groups in com-
parison to baseline (p< 0.005), but Levosimendan group was
signiﬁcantly lower than control groups (p< 0.001), then
started to increase during ICU course in the two groups but
still below baseline. Cardiac index showed a signiﬁcant in-
crease in both groups post CPB with marked improvement
in Levosimendan group, which started 15 min post CPB then
continued during ICU course. The increases were signiﬁcantly
higher in the Levosimendan group than in the control group
(p< 0.001). SVO2 values showed signiﬁcant improvement in
both groups post CPB and during ICU course (p< 0.05), with
much more increase in Levosimendan group only at T1 and T2
(p= 0.003 and 0.001, respectively).
The number of patients who required norepinephrine dur-
ing the weaning of CPB to maintain perfusion pressure was
signiﬁcantly greater in the levosimendan group (ﬁve patients)
than in the control group (two patients) (p< 0.05). Dobuta-
mine was needed for ﬁve patients in the placebo group and
for four patients in the levosimendan group.Table 1 Demographic data and risk factors.
Levosimendan
(n= 10)
Placebo
(n= 10)
p-value*
Age (year) 60 ± 10 58 ± 8 0.627
Sex (M/F) 8/2 7/3 1.000
BSA 1.92 ± 0.16 1.89 ± 0.10 0.621
Ejection fraction 36 ± 2 38 ± 3 0.096
Risk factors (no of patients)
Diabetes 9 7 0.576
HTN 7 5 0.648
COPD 3 1 0.576
Medication (no of patients)
ACE inhibitors 5 4 1.000
b blockers 10 10 1.00
Data are presented as mean ± SD and ratio for sex.
BSA, body surface area; HTN, hypertension; COPD, chronic
obstructive pulmonary disease.
* p-value levo. vs placebo.Graft ﬂow values of TTFM are shown in Table 4, Figs. 2
and 3. In both groups, ﬂow curve patterns were mainly during
diastole with minimal systolic peaks. In comparison to control
group, the mean ﬂow in all grafts was signiﬁcantly higher in
the Levosimendan group 30 min after CPB (p< 0.05). When
we compared mean ﬂow between different types of grafts in
the same group, in the Levosimendan group, we found that ve-
nous sequential grafts had higher ﬂow than non-sequential
graft (p< 0.001) and arterial grafts (p= 0.005). Also the
SVG had higher ﬂow in comparison to LIMA grafts
(p= 0.004).
As regard PI, it was statistically signiﬁcant (lower values) in
the Levosimendan group when compared to the control group
in all grafts (p< 0.001). When we compared PI values between
different types of grafts in the same group, we found that in the
Levosimendan group, there were no statistically signiﬁcant dif-
ferences (p= 0.8704) between LIMA and SVG but when we
compared PI between sequential grafts and SVG, it was more
signiﬁcant in sequential grafts (p= 0.002) and also it was more
signiﬁcant in comparison to LIMA grafts (p= 0.0027).
Two grafts, one graft in levosimendan group and one in
placebo group, in whom unsatisfactory TTFM ﬁndings were
detected the mean ﬂow & PI values were 14 ml/min & 4.2
and 14 ml/min & 5.0, respectively. Revision of the anastomosis
was performed and the operation was ended when a good ﬂow
was within satisfactory ranges (Figs. 4 and 5).
Troponin-I and arterial lactate release were detected in both
groups post-operatively with signiﬁcantly higher values
(p< 0.001) in control group (Table 5). The time for extuba-
tion in ICU was insigniﬁcant among the two studied groups
and the postoperative course of the patients was uneventful.
4. Discussion
In the present study, we investigated the effect of levosimendan
infusion on coronary grafts blood ﬂow (CBF) in ischemic pa-
tients with LV dysfunction who underwent CABG surgery and
we found a marked improvement in hemodynamic parameters
and Coronary blood ﬂow; greater in both arterial and saphe-
Table 3 Hemodynamic and oxygenation variables.
Each group (10 patients) Baseline (T0) 15 min post CPB (T1) End of surgery (T2) ICU 6 h (T3) ICU 24 h (T4)
HR (beat/min)
Levosimendan 62 ± 2.2 85 ± 2.4* 93 ± 2.1*,** 94 ± 1.5*,** 91 ± 1.4*,**
Placebo 63 ± 2.1 81 ± 1.8* 82 ± 1.3* 80 ± 2* 82 ± 1.2*
MAP (mm Hg)
Levosimendan 63 ± 2.5 82 ± 1.2*,** 85 ± 2.2*,** 92 ± 1.2*,** 93 ± 1.5*,**
Placebo 63 ± 2.2 76 ± 2.2* 82 ± 1.2* 83 ± 1.5* 81 ± 2*
PCWP (mm Hg)
Levosimendan 17 ± 1.5 15 ± 1.4 13 ± 1.5* 15 ± 1.7 14 ± 1.4
Placebo 16 ± 1.4 16 ± 1.6 13 ± 1.1* 14 ± 1.0 15 ± 1.4
CVP (mm Hg)
Levosimendan 7 ± 2 11 ± 3 12 ± 1 9 ± 2 10 ± 3
Placebo 8 ± 1 12 ± 4 10 ± 2 9 ± 3 8 ± 4
SVRI (dyne/s/cm5/m2)
Levosimendan 1859 ± 31.4 1027 ± 13.8*,** 1169 ± 11.9*,** 1250 ± 10.8*,** 1366 ± 8.8*,**
Placebo 1870 ± 6.5 1221 ± 7.5* 1281 ± 5.2* 1459 ± 9.0* 1638 ± 6.9*
PVRI (dynes/s/cm5/m2)
Levosimendan 262 ± 10.3 95 ± 5.8*,** 125 ± 7.0*,** 183 ± 7.1*,** 245 ± 11.9**
Placebo 273 ± 5.8 175 ± 4.5* 210 ± 4.0* 193 ± 4.9* 223 ± 4.7*
CI (L/min/m2)
Levosimendan 1.8 ± 0.2 3.8 ± 0.4*,** 3.4 ± 0.2*,** 3.7 ± 0.2*,** 2.7 ± 0.2*,**
Placebo 1.8 ± 0.3 2.7 ± 0.2* 2.6 ± 0.2* 2.4 ± 0.17* 2.5 ± 0.18*
SVO2 (%)
Levosimendan 64 ± 4. 4 74 ± 3.9*,** 77 ± 3.0*,** 71 ± 2.4* 75 ± 3.1*
Placebo 64 ± 4.5 68 ± 2.5 71 ± 3.2* 71 ± 4.4* 74 ± 2.6*
Data are presented as mean ± SD.
HR, heart rate; MAP, mean arterial pressure; PCWP, pulmonary capillary wedge pressure; SVRI, systemic vascular resistance index; SvO2,
mixed venous oxygen saturation; PVRI, pulmonary vascular resistance index; CI, cardiac index.
* p< 0.05 vs. baseline.
** p< 0.05 levo. vs. placebo.
Table 4 Comparison of the TTFM values between the two groups.
Mean ﬂow p-value 95% CI P I p-value 95% CI
Lower bound Upper bound Lower bound Upper bound
LIMA–LAD
Levo 50.15 ± 13.5* 0.016 37.6 62.7 2.4 ± 0.27* <0.001 2.2 2.6
Placebo 34.7 ± 12.3 23.1 46.4 4.1 ± 0.37 4.0 4.5
SVG-diagonal
Levo 55.29 ± 12.4* 0.024 43.5 67.0 3.1 ± 0.17* <0.001 3.0 3.3
Placebo 40.7 ± 14.0 27.9 53.6 4.2 ± 0.2 4.0 4.4
SVG–Cx system
Levo 56.7 ± 13.4* 0.003 44.4 69.2 2.1 ± 0.2* <0.001 2.0 2.3
Placebo 36.6 ± 12.5 24.8 48.5 2.7 ± 0.3 2.5 3.0
SVG–RCA system
Levo 56.5 ± 12.6* 0.004 44.7 68.2 2.2 ± 0.4* <0.001 2.2 2.7
Placebo 38.8 ± 11.4 27.8 49.9 3.9 ± 0.3 4.0 4.5
Sequential
Levo 77.6 ± 13.3* 0.016 65.3 90.1 1.8 ± 0.2* <0.001 1.6 2.0
Placebo 60.7 ± 15.2 47.1 74.4 2.4 ± 0.4 2.17 2.8
Data are presented as mean ± SD.
LIMA–LAD, left internal mammary artery–left anterior descending artery; SVG-diagonal, Savenous vein graft-diagonal; Cx system, circumﬂex
system, RCA system, right coronary artery system.
* p-value, levo. vs. placebo group.
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dan group, there was a tendency towards higher ﬂow in
sequential venous grafts than venous non-sequential and arte-
rial grafts. To our knowledge, no previous study examined theeffect of Levosimendan on coronary grafts ﬂow assessed by
TTFM.
Changes in graft ﬂow may be due to a direct drug effect on
the conduit, coronary vasculature, or a mixture of causes.
Figures 2 and 3 Normal TTFM values in LIMA–LAD and SVG sequential in Levosimendan group.
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function also inﬂuence the graft ﬂow. Other factors include
the surgical technique and competitive ﬂow through native ves-
sels [11]. So, coronary ﬂow is considered complex and depen-
dent on a large number of dynamic and non-dynamic factors.
Graft ﬂow in our study most probably related to changes in
hemodynamics and coronary vascular resistance. CI was signif-
icantly higher in the Levosimendan group, indicating a better
cardiac output possibly because of reduced systemic vascular
resistance and increased HR. These ﬁndings were coinciding
with the study of Lilleberg et al. [2] who documented a signiﬁ-
cant improvement of CBF and systemic hemodynamics in 23
patients randomized to placebo or two different doses of levo-
simendan after CABG surgery. Also previous studies [12–15]
had demonstrated a vasorelaxant effect of levosimendan on
smooth muscle tone of epicardial coronary artery preparations
obtained from porcine and human donor hearts.
All venous grafts in our study are manually dilated before
being anastomosed, so the effect of Levosimendan on ﬂow in
SVGs cannot be explained only by graft dilation. It could bedilation in the native peripheral coronary vessels. A recent
study by Maslow et al. [16] comparing vasoactive agents on
ﬂow during peripheral vascular surgery suggests that factors
affecting SVG ﬂow are not just simply related to systemic
hemodynamics. The usual technique of preparing saphenous
vein grafts, as used in our study, is known to damage all layers
of the vessel wall and may inﬂuence its normal reactivity [17].
A recent work by Tsui et al. [18] and Souza et al. [19] designed
to preserve integrity of vessel wall called ‘‘no-touch’’ harvest-
ing technique has been described. The long-term patency rate
was signiﬁcantly higher compared with conventionally treated
vein grafts.
An electrophysiological studies by Yokoshiki and his
colleagues [20] found that Levosimendan activates the gliben-
clamide-sensitive K + channel in rat arterial myocytes, sug-
gesting that the vasodilator effects of Levosimendan are
mediated through opening of the ATP sensitive potassium
channel in vascular smooth muscle cells.
In the study by Lilleberg et al. [2] Levosimendan decreased
systemic and pulmonary vascular resistance and increased cor-
Figures 4 and 5 Unsatisfactory TTFM ﬁndings in patients with SVG-OM and SVG-diagonal.
Table 5 Biochemical proﬁles.
Each group = 10 patients Baseline On ICU admission ICU 6 h ICU 24 h
Troponin-I (ng/ml)
Levosimendan 0.13 ± 0.02 2.3 ± 0.14* 2.5 ± 0.14* 3.1 ± 0.16*
Placebo 0.12 ± 0.01 2.5 ± 0.19*,** 5.2 ± 0.24*,** 7.6 ± 0.27*,**
Lactate (mmol/l)
Levosimendan 0.72 ± 0.2 1.6 ± 0.14* 1.8 ± 0.19* 2.2 ± 0.17*
Placebo 0.73 ± 0.2 1.8 ± 0.19*,** 2.5 ± 0.16*,** 3.1 ± 0.2*,**
Data are presented as mean ± SD.
* p< 0.005 vs. baseline.
** p< 0.001 levo. vs. placebo.
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cardial oxygen consumption or substrate extractions did not
change statistically signiﬁcantly. In our study, troponin-I and
lactate releases occurred in either of the groups but it was sig-
niﬁcantly higher in control group. These ﬁndings may indicate
that myocardial ischemia and impaired tissue perfusion were
mild in Levosimendan group in comparison to placebo group.
The efﬁcacy of Levosimendan in myocardial ischemia was
evaluated by previous studies on animal models of globaland regional ischemia [21] or in patients with acute myocardial
infarction (AMI) [22]. In the study by Moiseyev et al. [23],
which randomized 504 patients with LV failure complicating
an AMI, patients treated by Levosimendan showed lower risk
of death and worsening heart failure than patients receiving
placebo. In the study by Sonntag and his colleagues [24], to
investigate the effect of levosimendan on stunned myocardium,
they compared the effects of levosimendan to placebo on LV
function in 24 patients with acute coronary syndrome after a
52 O.M. Asaad, M.S. Hanafycoronary angioplasty. They recorded LV pressures and vol-
umes 10 min after angioplasty and 20 min after drug adminis-
tration. A leftward and/or upward shift of the systolic part of
the pressure–volume loop was observed, indicating improved
systolic function.
Ve´gh et al. [25] have shown in anaesthetized dogs, after
experimental acute heart failure induced by ligation of the
LAD and critical constriction of the left circumﬂex artery, that
levosimendan increased coronary blood ﬂow and myocardial
contractility.
In our study, we found a signiﬁcant improvement of CI and
CBF in patients with moderate LV dysfunction who under-
went CABG surgery. These ﬁndings were in agreement with
the study of Slawsky and his colleagues [26], on hemodynamics
and clinical effects of levosimendan in patients with severe
heart failure. They found that, levosimendan caused dose-
dependent decreases in PCWP, right atrial, and mean arterial
pressures and a concomitant increase in CI.
Many studies [7,8] recommended the wide use of TTFM
intraoperatively to detect graft patency, because they consid-
ered it noninvasive, easy to handle and represent the real ﬂow
within the graft. However, the same studies [7,8], documented
the potential factors that could affect TTFM values like hemo-
dynamic changes, distal coronary resistance, and graft diame-
ter. In our study we tried to maintain MAP between 80 and
90 mm Hg during the ﬂow measurement. Practically, we can-
not rely on mean graft ﬂow as the only measure to diagnose
intraoperative poor graft anastomoses. In the study by Jaber
et al. [27] demonstrated that mean graft ﬂow did not decrease
signiﬁcantly until graft stenosis was greater than 75%. The
pulsatility index value is considered another good indicator
of graft quality. The lower limit value of the pulsatility index
to conﬁrm successful graft patency has been suggested to be
less than ﬁve [28]. Gabriele and his colleagues [7], discussed
the main obstacle for wider use of TTF technology until
now, and they found that no clear-cut values for TTFM mea-
surements and lack of objective parameters to predict graft
failure.
There is one limitation in our study, the use of other vaso-
active drugs (dobutamine and norepinephrine) was an addi-
tional confounding factor, therefore, interaction between
levosimendan and norepinephrine is possible. Thereby, the
overall effects on different vascular beds may be unpredictable.
In conclusion, Levosimendan, given intravenously during
CABG surgery in patients with LV dysfunction, signiﬁcantly
improved hemodynamics and coronary blood ﬂow compared
with placebo.References
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